Pfizer reported second-quarter 2025 revenue of $14.65 billion, topping analysts’ consensus of about $13.5 billion and rising 10 % from a year earlier. Adjusted earnings came in at $0.78 a share versus the projected $0.58, while net income reached $2.91 billion, or $0.51 per share on a reported basis. After the stronger-than-expected quarter, the New York-based drugmaker lifted its full-year adjusted profit forecast to a range of $2.90 to $3.10 a share, up 10 cents at each end, and reaffirmed its revenue outlook of $61 billion to $64 billion. The new guidance absorbs one-time charges tied to a licensing deal with China’s 3SBio, the impact of 145 % U.S. tariffs on certain imports from China, Canada and Mexico, and potential price adjustments linked to most-favoured-nation rules. Pfizer said efficiency measures are tracking ahead of plan and reiterated that it expects to generate $7.2 billion in net cost savings by the end of 2027, with about $4.5 billion due by 2025. Chief Financial Officer David Denton signalled additional reductions over the next two years. Management also cited a weaker dollar as a tail-wind for earnings. The update comes as the company confronts slowing Covid-19 product sales and approaching patent expirations for key therapies. Investors welcomed the results, sending the shares up roughly 3 % in pre-market trading on Tuesday.